Početna › Rak jajnika
Kliničke studije za Rak jajnika koje traže sudionike u SAD-u
263 studija za Rak jajnika traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX89 studija
- New York City, NY69 studija
- Boston, MA61 studija
- Los Angeles, CA50 studija
- Nashville, TN49 studija
- Arlington, VA46 studija
- Philadelphia, PA44 studija
- Columbus, OH39 studija
- St. Louis, MO38 studija
- Chicago, IL36 studija
- San Antonio, TX31 studija
- Cleveland, OH30 studija
- Pittsburgh, PA30 studija
- Seattle, WA30 studija
- Atlanta, GA29 studija
- Rochester, MN29 studija
- Dallas, TX28 studija
- Oklahoma City, OK28 studija
- Queens, NY28 studija
- Durham, NC27 studija
- Portland, OR27 studija
- Detroit, MI26 studija
- Aurora, CO25 studija
- Baldwin Park, CA25 studija
- Minneapolis, MN24 studija
- San Diego, CA24 studija
- Grand Rapids, MI24 studija
- Birmingham, AL23 studija
- Washington, DC23 studija
- Miami, FL23 studija
- Orlando, FL22 studija
- Baltimore, MD22 studija
- New Haven, CT21 studija
- Tampa, FL21 studija
- Edison, NJ20 studija
- Salt Lake City, UT19 studija
- Cincinnati, OH19 studija
- Mountain View, CA19 studija
- San Francisco, CA19 studija
- Milwaukee, WI17 studija
Po državama
- Alabama27 studija
- Aljaska7 studija
- Arizona26 studija
- Arkansas11 studija
- Colorado44 studija
- Connecticut28 studija
- Delaware5 studija
- Distrikt Columbia7 studija
- Florida81 studija
- Georgia35 studija
- Havaji7 studija
- Idaho4 studija
- Illinois49 studija
- Indiana23 studija
- Iowa10 studija
- Kalifornija105 studija
- Kansas10 studija
- Kentucky25 studija
- Louisiana19 studija
- Maine9 studija
- Maryland40 studija
- Massachusetts67 studija
- Michigan50 studija
- Minnesota53 studija
- Mississippi6 studija
- Missouri41 studija
- Montana10 studija
- Nebraska15 studija
- Nevada11 studija
- New Hampshire4 studija
- New Jersey40 studija
- New Mexico16 studija
- New York96 studija
- North Carolina44 studija
- North Dakota7 studija
- Ohio70 studija
- Oklahoma31 studija
- Oregon34 studija
- Pennsylvania69 studija
- Rhode Island16 studija
- South Carolina17 studija
- South Dakota16 studija
- Tennessee55 studija
- Texas122 studija
- Utah29 studija
- Virginia57 studija
- Washington38 studija
- West Virginia10 studija
- Wisconsin29 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
U tijeku regrutacijaFaza 2
Sve dobne skupine · Oba spola · Ažurirano 2. lis 2026. · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04585750Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
U tijeku regrutacijaOpažajna studija
Od 2 do 100 godina · Oba spola · Ažurirano 2. lis 2026. · NCT01950572Distance-Based Exercise to Preserve Function and Prevent Disability
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06465069Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 2. lis 2026. · NCT04847063Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06885697A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06270706Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
U tijeku regrutacijaOpažajna studija
Od 3 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT01441089Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
U tijeku regrutacijaFaza 2
Od 18 do 72 godina · Oba spola · Ažurirano 2. lis 2026. · NCT01174121A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
U tijeku regrutacijaFaza 1
Od 19 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 1. lis 2026. · NCT07024784A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07189871TLR9 Immunotherapy for Peritoneal Carcinomatosis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07658196Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 1. lis 2026. · NCT07851025Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT04751435The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07285044A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07278336A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07814248Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07360314First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT06799065A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 29. ruj 2026. · NCT05128825Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.